Posledná aktualizácia :
19/11/2024
výskumné tímy - Universidad Complutense de Madrid,Facultad de Farmacia   PDF  
Španielsko
Univerzita
Universidad Complutense de Madrid,Facultad de Farmacia
Madrid
Odkazy na literatúru   Odkazy na literatúru   (12)  
1
Stability of daptomycin reconstituted vials and infusion solutions.
Ferrandez J, Sanchez R, Diaz D, Diaz M, Estevan M, Garcia T. (sanchez@salud.madrid.org)
EJHP - 2018 - ; 25: 107-110.
2
Stability of carboplatin infusion solutions used in desensitization protocol.
Vazquez-Sanchez R, Sanchez-Rubio-Ferrandez J, Cordoba-Diaz D, Cordoba-Diaz M, Molina-Garcia T. (rovazsan@hotmail.com)
J Oncol Pharm Practice - 2018 - 25,5:1076?1081
3
Compatibility and stability of ternary admixtures of tramadol, haloperidol, and hyoscine.
Negro S, Martin A, Azuara L, Sanchez Y, Barcia E. ()
J Palliat Med - 2010 - ; 13, 3: 273-277.
4
Tramadol and hyoscine N-butyl bromide combined in infusion solutions: compatibility and stability.
Barcia E, Martin A, Azuara ML, Sanchez Y, Negro S. (ebarcia@farm.ucm.es)
Support Care Cancer - 2007 - ; 15: 57-62.
5
Compatibility and stability of tramadol and dexamethasone in solution and its use in terminally ill patients.
Negro S, Salama A, S?nchez Y, AzuaraM.L, Barcia B. (soneal@farm.ucm.es)
J Clin Pharm Ther - 2007 - ; 32: 441-444.
6
Morphine, haloperidol and hyoscine N-butyl bromide combined in sc infusion solutions : compatibility and stability evaluation in terminal oncology patients.
Negro S, Reyes R, Azuara ML, Sanchez Y, Barcia E. (soneal@farm.ucm.es )
Int J Pharm - 2006 - ; 307: 278-284.
7
Compatibility and stability of furosemide and dexamethasone combined in infusion solutions.
Negro S, Rendon AL, Azuara ML, S?nchez Y, Fern?ndez-Carballido A, Barcia E. ( soneal@farm.ucm.es)
Arzneimittel Forschung - 2006 - ; 56, 10: 714-720.
8
Stability and compatibility of binary mixtures of morphine hydrochloride with hyoscine-n-butyl bromide.
Barcia E, Reyes R, Azuara L, Sànchez Y, Negro S. ()
Support Care Cancer - 2005 - ; 13, 4: 239-245.
9
Stability of tramadol and haloperidol for continuous infusion at home.
Negro S, Martin A, Azuara ML, Sanchez Y, Barcia E. ()
J Pain Symptom Manage - 2005 - ; 30: 192-199.
10
Stability study of an aqueous formulation of captopril at 1 mg/ml.
Escribano Garcia MJ, Torrado Duran S, Torrado Duran JJ. (torrado2@farm.ucm.es)
Farm Hosp - 2005 - ; 29: 30-36.
11
Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care.
Barcia E, Reyes R, Azuara M.L, S?nchez Y, Negro S. ()
Support Care Cancer - 2003 - ; 11, 2: 107-113.
12
Physical compatibility and in vivo evaluation of drug mixtures forsubcutaneous infusion to cancer patients in palliative care.
Azuara ML, Sanchez Y, Reyes R, Barcia E. (soneal @eucmax.sim.ucm.es)
Support Care Cancer - 2001 -

Zoznam zlúčenín   Skúmané zlúčeniny   (11)  
antihypertenzívum Perorálny roztok Captopril
Protinádorová liečba Injekcia Carboplatin
antibiotikum Injekcia Daptomycin
Antiflogistikum Injekcia Dexamethasone sodium phosphate
diuretikum Injekcia Furosemide
neuroleptikum Injekcia Haloperidol lactate
antiemetikum Injekcia Metoclopramide hydrochloride
anxiolytikum Injekcia Midazolam hydrochloride
analgetikum Injekcia Morphine hydrochloride
muskarínový antagonista Injekcia Scopolamine N-butyl bromide
analgetikum Injekcia Tramadol hydrochloride

  Mentions Légales